8-HOUR BAYER
Clinical safety rating: caution
8-HOUR BAYER is an extended-release formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet activity, used for long-lasting relief of mild to moderate pain, fever reduction, and inflammation, as well as for cardiovascular prophylaxis.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
| Metabolism | Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid. |
| Excretion | Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile. |
| Half-life | 15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics). |
| Protein binding | 80-90% bound to albumin; binding is concentration-dependent and saturable. |
| Volume of Distribution | 0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis. |
| Bioavailability | Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release). |
| Onset of Action | Oral: 30-60 minutes for analgesic effect; peak plasma concentrations at 4-6 hours due to extended-release formulation. |
| Duration of Action | Oral: 8 hours (analgesic/antipyretic effect) due to sustained-release formulation; longer at higher doses. |
| Molecular Weight | 180.16 |
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Avoid in severe renal impairment (CrCl <30 mL/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval. |
| Liver impairment | Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function. |
| Pediatric use | Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated). |
| Geriatric use | Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding. |
| 1st trimester | Risk of premature closure of ductus arteriosus and oligohydramnios; avoid use. |
| 2nd trimester | Avoid use due to potential fetal renal impairment and ductal constriction. |
| 3rd trimester | Contraindicated; may cause premature closure of ductus arteriosus, oligohydramnios, and neonatal complications. |
Clinical note
Aspirin should be avoided during pregnancy, especially in the third trimester (risk of premature closure of ductus arteriosus, oligohydramnios, and bleeding). Low-dose aspirin (81 mg/day) may be used for high-risk conditions (e.g., preeclampsia prevention) under medical supervision.
| Placental transfer | Aspirin crosses the placenta; degree of transfer is dose-dependent. High doses (>325 mg/day) associated with fetal risks. |
| Breastfeeding | Aspirin passes into breast milk in low amounts. Risk of Reye syndrome in infants; avoid use, especially during viral illness. Use with caution only if necessary and monitor infant for adverse effects. |
■ FDA Black Box Warning
None
| Common Effects | Dyspepsia, Nausea, Heartburn, GI bleeding (occult), Tinnitus (high dose), Prolonged bleeding time, Rash |
| Serious Effects | GI hemorrhage, intracranial hemorrhage, renal failure, bronchospasm, Reye's syndrome (pediatric), anaphylaxis. |
Aspirin allergy (NSAID hypersensitivity)Active peptic ulcer disease or GI bleedingBleeding disorders (e.g., hemophilia, von Willebrand disease)Severe hepatic impairmentSevere renal impairment (CrCl <30 mL/min)Third trimester of pregnancyConcomitant use of methotrexate (≥15 mg/week)Children with viral illness (Reye syndrome risk)
| Precautions | Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - caution advised |
| Teratogenic Risk | First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn. |
| Fetal Monitoring | Monitor for signs of bleeding in both mother and fetus. Assess amniotic fluid volume if prolonged use. Fetal ultrasound to evaluate ductus arteriosus patency if used after 20 weeks gestation. |
| Fertility Effects | Aspirin may impair female fertility through inhibition of prostaglandin synthesis, potentially affecting ovulation and implantation. Reversible upon discontinuation. |
| Food/Dietary |
| Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels. |
| Clinical Pearls | 8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk. |
| Patient Advice | Take with a full glass of water; do not crush or chew the tablet. · Do not use within 7 days before surgery due to bleeding risk. · If used for pain, consult a doctor if symptoms persist for more than 10 days. · Avoid alcohol while taking this medication to reduce stomach bleeding risk. · Seek medical attention for signs of bleeding (black stools, blood in vomit). |